Ozempic is not FDA-approved for prediabetes. Its approved uses are limited to adults with type 2 diabetes: improving blood sugar control, reducing cardiovascular risk, and protecting kidney function. That said, some doctors do prescribe it off-label for prediabetes, and clinical trial data suggests it can significantly lower the chances of progressing to type 2 diabetes.
What Prediabetes Actually Means
Prediabetes is diagnosed when your blood sugar is elevated but not high enough to qualify as type 2 diabetes. The American Diabetes Association defines it as an A1C between 5.7% and 6.4%, a fasting blood sugar of 100 to 125 mg/dL, or a two-hour glucose tolerance test result between 140 and 199 mg/dL. Without intervention, a significant percentage of people with prediabetes go on to develop type 2 diabetes within several years.
What the Research Shows
The strongest evidence comes from the SELECT trial, which studied semaglutide (the active ingredient in Ozempic) in people with overweight or obesity who did not have diabetes. Many participants had prediabetes at the start. After three years, only 1.5% of people on semaglutide had progressed to diabetes, compared to 6.9% on placebo. That translates to a 73% reduction in the risk of developing type 2 diabetes. Researchers estimated that treating about 19 people with semaglutide for three years would prevent one new case of diabetes.
Blood sugar improvements appeared quickly. By 20 weeks, average A1C dropped to 5.45% in the semaglutide group versus 5.77% with placebo, a difference that held steady through the full three years of follow-up.
A separate trial, STEP 10, looked specifically at people with obesity and prediabetes. Participants on a higher dose of semaglutide (2.4 mg, the dose used in Wegovy rather than Ozempic) lost an average of 13.9% of their body weight over one year, compared to 2.7% with placebo. That level of weight loss on its own substantially improves insulin sensitivity and blood sugar regulation.
How It Works in Your Body
Semaglutide mimics a natural gut hormone called GLP-1 that your body releases after eating. This hormone signals your pancreas to produce more insulin when blood sugar rises, slows the rate at which your stomach empties food into the intestines, and reduces appetite by acting on hunger centers in the brain. The combined effect is lower blood sugar after meals, reduced calorie intake, and gradual weight loss. For someone with prediabetes, losing even 5% to 7% of body weight can be enough to bring blood sugar back into the normal range.
How Ozempic Compares to Metformin
Metformin is the most commonly prescribed medication for prediabetes and has decades of evidence behind it. It’s inexpensive, widely available as a generic, and most insurance plans cover it without issue. In studies, metformin reduces the risk of progressing from prediabetes to type 2 diabetes by about 31%.
Ozempic produces more weight loss. People with type 2 diabetes and obesity lost an average of 5% to 6% of body weight after a year on Ozempic, compared to roughly 2% after two years on metformin. The blood sugar reductions with semaglutide also tend to be larger. However, metformin costs a fraction of the price and doesn’t require injections, which is why it remains the first-line choice for most people with prediabetes who need medication beyond lifestyle changes.
Insurance and Cost Barriers
This is where the off-label status creates a real problem. Because Ozempic is only approved for type 2 diabetes, most insurance plans will not cover it for a prediabetes diagnosis. Prior authorization requirements have become increasingly strict even for approved uses, and insurers routinely deny claims when the prescribing diagnosis doesn’t match the drug’s label.
Without insurance, Ozempic can cost over $900 per month. Some doctors work around this by prescribing Wegovy (the same drug at a higher dose, approved for weight management) if a patient qualifies based on BMI, since obesity is a covered indication. But Wegovy faces its own access restrictions, and coverage varies widely between plans. If your doctor recommends semaglutide for prediabetes, it’s worth calling your insurer before filling the prescription to understand what you’ll actually pay.
What Off-Label Use Looks Like
When Ozempic is prescribed off-label, most people start at the same dose used for type 2 diabetes: 0.25 mg injected once a week for four weeks, then 0.5 mg for another four weeks, potentially increasing to 1.0 mg. In practice, a real-world survey of off-label users found that about 69% started at the recommended 0.25 mg dose, but only 20% followed the full standard dose escalation schedule. Many stayed at lower doses, either because they achieved results or because of side effects like nausea, which is the most common complaint during the first few weeks.
The injections use a pre-filled pen with a small needle and go into the abdomen, thigh, or upper arm. Most people find the injection itself straightforward after the first one or two doses.
The Bigger Picture for Prediabetes
Lifestyle changes remain the most effective and best-studied approach to reversing prediabetes. The landmark Diabetes Prevention Program trial showed that losing 7% of body weight through diet and exercise reduced the risk of developing type 2 diabetes by 58%, nearly double the effect of metformin alone. Semaglutide can make that weight loss easier to achieve, but it works best alongside the same dietary and activity changes that form the foundation of prediabetes management.
If your A1C is in the prediabetes range and lifestyle changes haven’t moved the needle, medication becomes a reasonable conversation to have. Metformin is the usual starting point given its cost, safety record, and insurance accessibility. Ozempic or Wegovy may enter the picture if weight loss is a primary goal or if metformin hasn’t been enough on its own, though you’ll likely need to navigate insurance hurdles to access it.